Kane Biotech Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KNE.V | IOT.V | CLGN | NIKI | BLRX | ET80.F | |
|---|---|---|---|---|---|---|
| Market cap | 6.15M | 3.54M | 7.03M | 6.05M | 10.30M | 5.35M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | — | -9.5 | — | -0.8 | — |
| Price/book | -6.0 | 1.4 | 1.8 | 0.1 | 0.7 | 0.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −25.00% | −68.18% | −83.49% | −86.67% | −42.35% | −14.10% |
| Today | 0.00% | 0.00% | −0.93% | −3.00% | −1.90% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KNE.V news ›Kane Biotech signs Canadian distribution agreement for revyve wound care
The non-exclusive Stevens agreement covers gel and spray formats, but Kane's announcement gives no minimum orders, pricing or revenue forecast. A new Canadian resale channel is being added as Kane Biotech Inc. CVEKNE announced a…
Kane Biotech Signs Distribution Agreement with The Stevens Company
October 20, 2026 07:05 ET | Source: Kane Biotech Inc. Kane Biotech Inc. Expands Kane Biotech’s commercial footprint and access to the revyve® product line across Canada Under the agreement, Stevens will be authorized to purchase and resell…
Kane Biotech Announces $250,000 Insider Loan
The Loan does not bear interest and is repayable on demand. No bonus was paid or is payable by the Company in connection with the Loan. The Company intends to use the proceeds for general working capital and corporate purposes and intends…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com5
-
globenewswire.com2
-
kalkinemedia.com2
-
stocktitan.net2
-
kdhnews.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.